Send the following on WhatsApp
Continue to Chat阿茲海默症新藥爭議未止,FDA 與百健遭受猛烈抨擊 https://geneonline.news/aduhelm-congressional-report-fda-biogen/?variant=zh-cn
阿茲海默症新藥爭議未止,FDA 與百健遭受猛烈抨擊 https://geneonline.news/aduhelm-congressional-report-fda-biogen/?variant=zh-cn